Cisplatin/carboplatin cross-resistance in ovarian cancer
Open Access
- 1 November 1989
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 60 (5), 767-769
- https://doi.org/10.1038/bjc.1989.356
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effectsCarcinogenesis: Integrative Cancer Research, 1988
- High-dose carboplatin in refractory ovarian cancer patients.Journal of Clinical Oncology, 1987
- A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma.Journal of Clinical Oncology, 1986
- MECHANISM OF CYTOTOXICITY OF ANTICANCER PLATINUM DRUGS - EVIDENCE THAT CIS-DIAMMINEDICHLOROPLATINUM(II) AND CIS-DIAMMINE-(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II) DIFFER ONLY IN THE KINETICS OF THEIR INTERACTION WITH DNA1986
- Ovarian trials at the Royal MarsdenCancer Treatment Reviews, 1985
- Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.1985
- PHASE-II STUDY OF JM8, A NEW PLATINUM ANALOG, IN ADVANCED OVARIAN-CARCINOMA1983
- Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy.1978
- Second trial drugs in ovarian cancerGynecologic Oncology, 1977
- PHASE-2 STUDY OF CIS-DICHLORODIAMMINEPLATINUM(II) (NSC-119875) IN ADVANCED ADENOCARCINOMA OF OVARY1976